Related Experiment Video
Updated: Jul 23, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Polyomavirus-associated nephropathy: update on antiviral strategies
M A Josephson1, J W Williams, A Chandraker
1Department of Medicine, University of Chicago, Illinois 60637, USA. mjosephs@medicine.bsd.uchicago.edu
Abstract:
Polyomavirus-associated nephropathy (PVAN) is a major complication of kidney transplantation. Many centers respond to PVAN by reducing immunosuppression. Concern over precipitating rejection, as well as situations in which some PVAN-afflicted individuals have multi-organ transplants, can make reduction of immunosuppression undesirable. In these cases, effective antiviral strategies would be useful. This article describes clinical observations and experiences with 3 different antiviral protocols. Two protocols address antiviral treatment of nephropathy (cidofovir in one, and leflunomide in the other). The third protocol examines fluoroquinolone control of polyoma urinary excretion. Patients responded to all 3 strategies. These promising approaches deserve further evaluation with prospective controlled studies.
Related Concept Videos
Myocarditis III: Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Nephrotic Syndrome II : Assessment and Medical Management
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

